Herborium(R) Group Discusses an Aftermath of the Ban of Diane-35 Acne Drug Due to Number of Deaths
FORT LEE, N.J., Feb. 4, 2013 /PRNewswire/ — Herborium Group, Inc., (OTC Pink: HBRM) www.herborium.com, a Botanical Therapeutics® Company discusses an impact of a ban of Bayer’s Diana-35 acne drug in Europe, and a follow up investigation in Canada, on Herborium’ s all botanical acne treatment -AcnEase®.
Diane-35 is a hormonal drug used to treat hormonal acne, especially those resulting from too much of androgens (male hormones). It is also an oral contraceptive (birth control pill). Diane-35 is not approved in the US but it was available in Canada. Like many other drugs Diane-35 found its way to US consumers though so called “gray marketing”.
Diane-35 is presently investigated in Europe and Canada for number of deaths, caused by blood clots, and for non-fatal cases of thrombosis and arterial thrombosis associated with a use of a drug.
In September 2011, the U.S. Food and Drug Administration (FDA) has informed the public that it has not yet reached a conclusion, but remains concerned, about the potential increased risk of blood clots with the use of drospirenone-containing birth control pills. Number of US approved contraceptive pills including very popular Yasmin and Yuz were put on a warning list. Despite of the warning, birth control pills are still rather liberally prescribed to women with acne even if their sexual activity is not a factor.
AcnEase® is all botanical ingredients based product that DOES NOT INCLUDE ANY ESTROGEN. Furthermore, AcnEase® also DOES NOT include any phytoestrogens (plant-derived estrogen-like substance). As phytoestrogens may be considered safer that those made chemically they still act in a similar way and therefore may not be suitable or safe for some consumers especially teens, women that want to become pregnant, those who are pregnant or nursing, and of course men suffering from hormonal acne.
“We are deeply saddened by a death and potential serious health implication among Diane-35 patients. We are also determined to reiterate to our investors and customers that a decision to base Herborium’s differential advantage on the use of proprietary, validated and safe botanical formulas has once again been proven correct and most advantageous both strategically and ethically. We will continue to provide safe and up to 96% effective AcnEase® to acne sufferers in all markets, and to grow our market share in the multi-billion dollar world-wide acne treatment sector,” commented Dr. Agnes P. Olszewski, CEO and Chairwomen of Herborium Group.
About Herborium Group, Inc.
Herborium Group, Inc., a Botanical Therapeutics® company, focuses on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company uses clinical validation to establish and maintain a differential advantage. The company sells its products in the US and Europe. For more information, please visit www.herborium.com and www.acnease.com
One of our most important responsibilities is to communicate with shareholders in an open and direct manner. Comments are based on current management expectations, and are considered “forward-looking statements,” generally preceded by words such as “plans,” “expects,” “believes,” “anticipates,” or “intends.” We cannot promise future returns. Our statements reflect our best judgment at the time, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events. The Company urges investors to review the risks and uncertainties contained within its filings with the OTC Markets and/or Securities and Exchange Commission.
For more information please inquire: Investorsrelations@herborium.com
SOURCE Herborium Group, Inc.